Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)LeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - Other
Ratios

Amylyx Pharmaceuticals (AMLX) Receivables - Net (2022 - 2025)

Amylyx Pharmaceuticals (AMLX) has 4 years of Receivables - Net data on record, last reported at $88000.0 in Q4 2025.

  • For Q4 2025, Receivables - Net fell 80.31% year-over-year to $88000.0; the TTM value through Dec 2025 reached $88000.0, down 80.31%, while the annual FY2025 figure was $88000.0, 80.31% down from the prior year.
  • Receivables - Net reached $88000.0 in Q4 2025 per AMLX's latest filing, down from $132000.0 in the prior quarter.
  • Across five years, Receivables - Net topped out at $40.0 million in Q4 2023 and bottomed at $88000.0 in Q4 2025.
  • Average Receivables - Net over 4 years is $11.7 million, with a median of $2.9 million recorded in 2024.
  • Peak YoY movement for Receivables - Net: soared 21325.55% in 2023, then plummeted 98.88% in 2024.
  • A 4-year view of Receivables - Net shows it stood at $15.3 million in 2022, then surged by 161.66% to $40.0 million in 2023, then tumbled by 98.88% to $447000.0 in 2024, then tumbled by 80.31% to $88000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Net were $88000.0 in Q4 2025, $132000.0 in Q3 2025, and $103000.0 in Q2 2025.